Improved survival of adolescents and young adults patients with T-cell acute lymphoblastic leukemia

Amr Hanbali; Ahmed Kotb; Riad El Fakih; Feras Alfraih; Nahla Shihata; Walid Rasheed; Syed Osman Ahmed; Marwan Shaheen; Saud Alhayli; Ali Alahmari; Ahmad Alotaibi; Alfadel Alshaibani; Abdulwahab Albabtain; Mansour Alfayez; Maha Hassan; Fahad Alsharif; Naeem Chaudhri; Fahad Almohareb; Hazzaa Alzahrani; Mahmoud Aljurf

doi:10.2217/ijh-2022-0005

Improved survival of adolescents and young adults patients with T-cell acute lymphoblastic leukemia

Int J Hematol Oncol. 2023 Feb 27;12(1):IJH42. doi: 10.2217/ijh-2022-0005. eCollection 2023 Feb.

Authors

Amr Hanbali¹, Ahmed Kotb², Riad El Fakih¹, Feras Alfraih¹, Nahla Shihata³, Walid Rasheed¹, Syed Osman Ahmed¹, Marwan Shaheen¹, Saud Alhayli¹, Ali Alahmari¹, Ahmad Alotaibi¹, Alfadel Alshaibani¹, Abdulwahab Albabtain¹, Mansour Alfayez¹, Maha Hassan¹, Fahad Alsharif¹, Naeem Chaudhri¹, Fahad Almohareb¹, Hazzaa Alzahrani¹, Mahmoud Aljurf¹

Affiliations

¹ Division of Hematology, Stem cell transplantation & Cellular therapy, Oncology Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
² Department of Medicine, Hematology unit, Zagazig University, Egypt.
³ King Faisal Specialist Hospital, Jeddah, Saudi Arabia.

Abstract

Aim: The outcome of T-cell acute lymphoblastic leukemia (T-ALL) has improved with the use of pediatric-inspired protocols in the adolescents and young adults (AYA) population. There is limited literature regarding the outcome of T-ALL/lymphoblastic lymphoma (LBL) AYA patients treated with pediatric protocols.

Methods: A total of 35 T-ALL/LBL-AYA patients ages between 14 and 55 years were treated with AYA-15 protocol.

Results: At a median follow-up of 5 years the overall survival, disease-free survival and event-free survival are 71%, 62% and 49.6% respectively. Toxicities were within the expected range.

Conclusion: Our single-center experience real-world data in treating T-ALL/LBL-AYA patients with pediatric-inspired protocol demonstrates encouraging results of high survival rate and excellent tolerability for patients aged 18-55 years.

Keywords: T cell; acute lymphoblastic leukemia; adolescents and young adults; pediatric-inspired chemotherapy; real-world data.